Professor David Price
Chair of Primary Care Respiratory Med
- About
-
- Email Address
- d.price@abdn.ac.uk
- Telephone Number
- +44 (0)1224 437237
- School/Department
- School of Medicine, Medical Sciences and Nutrition
- Publications
-
Page 16 of 86 Results 151 to 160 of 859
A pragmatic primary practice approach to using specific IgE in allergy testing in asthma diagnosis, management, and referral
Journal of Asthma and Allergy, vol. 2022, no. 15, pp. 1069—1080Contributions to Journals: ArticlesCorrespondence to Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA2LEN consensus
Allergy, vol. 77, no. 8, pp. 2571-2573Contributions to Journals: Letters- [ONLINE] DOI: https://doi.org/10.1111/all.15281
- [ONLINE] View publication in Scopus
COPD Population in US Primary Care: Data From the Optimum Patient Care DARTNet Research Database and the Advancing the Patient Experience in COPD Registry
Annals of Family Medicine, vol. 20, no. 4, pp. 319-327Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1370/afm.2829
Oral corticosteroid (OCS) risk predictor for Type II Diabetes in asthma
European Respiratory Society (ERS) International Congress.Contributions to Conferences: AbstractsA Response to: Letter to the Editor Regarding “Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab”
Advances in Therapy, vol. 39, no. 8, pp. 3862-3865Contributions to Journals: LettersPersistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study
Aspen Allergy Conference – 40th MeetingContributions to Conferences: AbstractsPersistent OCS reduction regardless of starting OCS dose in patients with severe, OCS-dependent asthma treated with dupilumab: LIBERTY ASTHMA TRAVERSE study
15º Congreso ALAT 2022Contributions to Conferences: AbstractsCharacterisation of the Australian adult population living with asthma: Severe exacerbation frequency, long-term OCS use and adverse effects.
Pragmatic and Observational Research, vol. 2022, pp. 43-58Contributions to Journals: ArticlesHealthcare resource utilisation associated with intermittent oral corticosteroid use in asthma
EAACI HYBRID CONGRESS 2022Contributions to Conferences: AbstractsBiologics in severe asthma: the role of real-world evidence from registries
European Respiratory Review, vol. 31, no. 164, 210278Contributions to Journals: Articles